Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents
Authors
Keywords
Breast cancer, Primary culture, Hormone receptor, Prognostic marker, Cancer stem cells, CD44, CD24, <em class=EmphasisTypeItalic >IFIT3</em>, Interferon-α, snoRNA
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-09
DOI
10.1186/s12885-018-4635-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IFIT3 and IFIT2/3 promote IFIT1-mediated translation inhibition by enhancing binding to non-self RNA
- (2018) Renata C Fleith et al. NUCLEIC ACIDS RESEARCH
- Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma
- (2017) Yingyun Yang et al. HEPATOLOGY
- Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma
- (2017) Yue Zhao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens
- (2016) Mark Laible et al. BMC CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer
- (2016) H. Singhal et al. Science Advances
- Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases
- (2016) Yoshiya Horimoto et al. PLoS One
- Cancer stem cell and epithelial–mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast
- (2015) Ming Liang Oon et al. BREAST CANCER RESEARCH AND TREATMENT
- Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
- (2015) Marie-Emmanuelle Legrier et al. BRITISH JOURNAL OF CANCER
- Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin
- (2015) OlgaA Koval et al. Journal of Cancer Research and Therapeutics
- Potential role for snoRNAs in PKR activation during metabolic stress
- (2015) Osama A. Youssef et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Markers for Breast Cancer: Prediction on Tumor Behavior
- (2014) Bruna Karina Banin Hirata et al. DISEASE MARKERS
- Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
- (2014) Paul Geeleher et al. GENOME BIOLOGY
- Molecular and Cellular Heterogeneity in Breast Cancer
- (2013) Ashley G. Rivenbark et al. AMERICAN JOURNAL OF PATHOLOGY
- Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- (2013) Sohita Dhillon DRUGS
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune system and inflammation in breast cancer
- (2013) Xinguo Jiang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer
- (2012) Julia Y. S. Tsang et al. BREAST CANCER RESEARCH AND TREATMENT
- Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics
- (2012) Danielle N. Van et al. FASEB JOURNAL
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact
- (2011) Chiara Foroni et al. CANCER TREATMENT REVIEWS
- CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome
- (2011) Michael O. Idowu et al. HUMAN PATHOLOGY
- An adult tissue-specific stem cell molecular phenotype is activated in epithelial cancer stem cells and correlated to patient outcome
- (2010) Thomas Hussenet et al. CELL CYCLE
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized medicine in oncology: the future is now
- (2010) Richard L. Schilsky NATURE REVIEWS DRUG DISCOVERY
- Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
- (2009) Shuzhen Liu et al. BREAST CANCER RESEARCH AND TREATMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More